Framework of the Report
Main Conclusions
Key Findings
I. Overview of the Global Bio-Pharmaceutical Industry in 2006
　　(I) Market Size and Characteristics
　　　　1. Market Size and Growth in 2006
　　　　2. Market Characteristics in 2006
　　　　3. Application of New Technologies
　　(II) Major Countries & Regions
　　　　1. U.S.A
　　　　2. Europe
　　　　3. Denmark
　　　　4. Singapore
II. Overview of China's Bio-Pharmaceutical Industry, 2005-2006
　　(I) Development Environment
　　　　1. Policy Environment
　　　　2. Investment Environment
　　　　3. Market Environment
　　　　4. Information Service Environment
　　(II) Present Situation
　　　　1. Industry Size
　　　　2. Molecular Biological Materials
　　　　3. Pharmaceutical Materials
　　　　4. Biological Equipment and Methods
　　　　5. Biological Evolution and Ecological Materials
　　　　6. Plant Materials
　　　　7. Animal Materials
　　(III) Characteristics
　　　　1. New technology becomes main conventional methods in the development of bio-pharmaceuticals
　　　　2. Bio-pharmaceutical enterprises engaged in closer cooperation, with finer division of work
　　　　3. The high-end R&D of new products dramatically boosts the industry's competitiveness
　　　　4. Outsourcing becomes bio-pharmaceutical enterprises' important development strategy
　　(IV) Existing Problems
　　　　1. Low Industrialization Degree, Long Product Cycle
　　　　2. Low Innovation Degree, Lack of Key Technology
　　　　3. Loose Market Regulation, Decreased Product Credit
　　(V) Industry Segments
　　　　1. Genetic Engineering Drugs
　　　　2. Antibody Engineering Pharmaceutics
　　　　3. Blood Products
　　　　4. Vaccines
　　　　5. Diagnosis Reagents
　　　　6. Biochips
　　　　7. Chemical Medicine
　　　　8. Traditional Chinese Medicine
III. Analysis of the Industry Chain of China's Bio-Pharmaceutical Industry in 2006
　　(I) Structure of Industry Chain
　　　　1. Technology Platform
　　　　2. Research & Development
　　　　3. Clinical Drugs
　　　　4. Translating Research Results into Products
　　　　5. Channels
　　(II) Present Situation of Supply & Demand in the Industry Chain
　　(III) Characteristics of the Industry Chain & Problems
　　　　1. Basic technology platforms are completed but underutilized
　　　　2. Cross-regional transfer of product technology is brisk but somewhat blind
　　　　3. Despite strong R&D capability, the loss of R&D results is alarming
IV. Analysis of the Competitiveness of China's Bio-Pharmaceutical Industry in 2006
　　(I) Competition Model
　　　　1. Product Price
　　　　2. Brand Competition
　　　　3. Channel Competition
　　　　4. Technical Competition
　　(II) Competition Situation
　　　　1. Overall Competition Situation
　　　　2. Potential Entrants and Substitute Products
　　　　3. Distribution of Leading Brands
　　(III) Leading Brands' Strategies
　　　　1. Tiantan Biological
　　　　2. Novo Nordisk
　　　　3. ...
V. Development Trend of China's Bio-Pharmaceutical Industry, 2007-2009
　　(I) Impetuses
　　　　1. Policy Factors
　　　　2. Economic Factors
　　　　3. Social Factors
　　　　4. Technical Factors
　　(II) Development Trend
　　　　1. Trend of Production and Consumption
　　　　2. Development Trend of Products
　　　　3. Trend of Technological Innovation
　　　　4. Trend of Competition
VI. Forecast of China's Bio-Pharmaceutical Industry, 2007-2009
　　(I) Analysis of Development Potential
　　(II) Forecast of Development
　　　　1. Forecast of Size
　　　　2. Forecast of Structure
VII. Investment Opportunities in China's Bio-Pharmaceutical Industry, 2007-2009

　　(I) Index System
　　(II) Investment Opportunities
VIII. Recommendations from Our.
　　(I) Strategic Recommendations
　　(II) Investment Recommendations


List of Tables
　　Size of China's Bio-Pharmaceutical Market, 2005-2006
　　Size of China's Genetic Engineering Drugs Market in 2006
　　Size of China's Antibody Engineering Pharmaceutics Market in 2006
　　Size of China's Blood Products Market in 2006
　　Size of China's Vaccine Market in 2006
　　Size of China's Biochip Market in 2006
　　
　　...

List of Figures
　　Size of the Global Bio-Pharmaceutical Market, 2006-2007
　　Development of the U.S.A Bio-Pharmaceutical Market, 2006-2007
　　Development of the European Bio-Pharmaceutical Market, 2006-2007
　　Development of the Danish Bio-Pharmaceutical Market, 2006-2007
　　Development of Singapore's Bio-Pharmaceutical Market, 2006-2007
　　...